Recently, two clinical trials addressed the role of tight blood glucose control on cardiovascular risk in people with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study and the Action in Diabetes and Vascular Disease (ADVANCE) trial. The ACCORD study included 10,251 people with type 2 diabetes and was designed to determine whether intensive blood glucose control (HbA1c below 6%) as compared to a conventional approach (HbA1c between 7% and 7.9%) would result in favourable cardiovascular outcomes in people with type 2 diabetes at high vascular risk. ADVANCE, involving 11,000 or so people with type 2 diabetes with a history of cardiovascular disease, also aimed to assess whether intensive blood glucose control could improve vascular outcomes. In this report, Luigi Gnudi compares and contrasts the methodologies behind and conclusions drawn from these investigations.
ACCORD, ADVANCE, cardiovascular health